July 24, 2018 5:26pm

Even I was surprised by the direction of “the bouncing share pricing” as the advance/decline line (A/DL) closed negative with 4/40 and 1 flat

Did the “algorithmic rules” barn door get left open?

 

Pre-open indications: 5 hits and 2 miss

Out and about: Verastem Oncology (VSTM) files for $200 M mixed shelf offering and Caladrius Bioscience (CLBS) files for $150 M mixed shelf offering

Quick look: BLUE’s (-$13.60) pricing gets whipped after proposing offering; AGTC’s (-$0.25) 1st patient and $10 M still doesn’t stem its decline; BCLI (+$0.18) bounces back after earnings release; ALNY (-$3.05) after positive results dives; BLFS (-$1.54) gets its come downance; while the gang that didn’t manage its expectation - BSTG (-$0.05) drops yet gain as CRISP equities – CRSP (-$5.46), EDIT (-$2.91) and NTLA (-$1.96) feel even more pain while share pricing declines are based on the rehashing of old news, yet NOT one of the editing companies have addressed the “issue” thus there are good reasons investors shouldn't be too quick to dismiss these cancer related concerns!

 

I say today what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  Want to know WHY, WHAT and HOW, subscribe!

Henry’omics:

 

The sector just executed a HUGE reversal ... as the NASDAQ saw its biggest reversal from a gain sice 2/21/18 with its intraday erosion of momentum.

 

At its peak, the index was up Tuesday by as many as 86.92 points, a gain of about 1.1%, only to limp out of the session with a loss

WHO was up: BCLI (+$0.18), IONS (+$0.76), MDXG (+$0.12), and VCEL (+$0.30) … and flat was OSIR

 

Of the 45 companies covered on Tuesday; 40 downside equities finished in a range of -$0.0009 (KOOL) to -$13.60 (BLUE) while the 4 upside equities oscillated from +$0.18 (BCLI) to $0.76 (IONS) with 1 flat closes.

 

The advance/decline line scenario of 45 covered companies:   

  • The open was positive with an A/DL of 24/19 and 2 flats;
  • The mid-day dived negative with an A/DL of 5/38 and 2 flats;
  • The close was negative with an A/DL of 4/40 and 1 flat;

 

Pre-open indications: 5 hit and 2 miss

  • bluebird bio (BLUE) closed down -$13.60 – hit;
  • Crispr (CRSP) closed down -$5.46 – hit;
  • Editas (EDIT) closed down -$2.91 – hit;
  • Intellia (NTLA) closed down -$1.96 – hit;
  • BioLife Solutions (BLFS) closed down -$1.54 – hit;
  • Regenxbio (RGNX) closed down -$4.25 – miss;
  • Verastem Oncology (VSTM) closed down -$0.05 – miss;

 

From the pre-open newsletter titled, “the oversold will rise again.” – and then they didn’t!

I also stated, “with the iShares Nasdaq Biotechnology (IBB) indicating a +0.81% UPSIDE in Tuesday’s pre-market – and WHAT happened it crashed -0.58%

 

The CHRISPR chronicles:

Tuesday: CRISPR stocks stayed in the tank in yet another session… CRSP (-$5.46 or -9.53%), EDIT (-$2.91 or -8.23%) and NTLA (-$1.96 or -6.44%). Another “shuffle” to the downside as I had stated, “it ain’t over as it falls precipitously in the day’s range!” Recent stock moves hint that the hype may need to come back down to earth, as there's much left to understand about using CRISPR tools in human cells. To date researchers have focused mostly on the ability to cut DNA, but it may be time to start paying closer attention to what happens after that! <MotleyFool>.

Monday the hits just kept coming as the gene “editors” downside drift continues:  CRISPR Therapeutics (CRSP -$1.08 or -1.85%); Editas Medicine (EDIT -$0.88 or -2.23%) and Intellia Therapeutics (NTLA -$1.17 or -3.70%) … investors are speaking to negative trust of researchers!

Friday: follow the bouncing share pricing, a session of speculation to the downside: CRISPR Therapeutics (CRSP -$0.04 or +0.07%); Editas Medicine (EDIT +$0.12 or +0.33%) and Intellia Therapeutics (NTLA -$0.01 or -0.03%) …

Thursday for gene editing companies was a day of “rhyme or reason” with the oversold getting yet again ready to be overbought again as trading speciation controlled the session: CRISPR Therapeutics (CRSP +$0.21 or +0.36%) stayed down for the count; Editas Medicine (EDIT +$0.75 or +2.12%) and Intellia Therapeutics (NTLA +$0.63 or +2.03%) … flew close to the flatlands to not melt their upside (the Icarus story) after …

Wednesday, what has speculation born: gene editing stocks dumped: Editas Medicine (EDIT -$1.08 or -2.96%), CRISPR Therapeutics (CRSP -$3.48 or -5.61%) and Intellia Therapeutics (NTLA -$0.36 or -1.15%) …

Last Tuesday, gene editing stocks high jumped in response to their dramatic decline: Editas Medicine (EDIT +$1.26 or +3.58%), CRISPR Therapeutics (CRSP +$1.95 or +3.25%) and Intellia Therapeutics (NTLA +$2.00 or +6.81%) …

The previous Monday, gene editing stocks dropped like stones in a lake: Editas Medicine (EDIT -$2.70 or -7.21%), CRISPR Therapeutics AG (CRSP -$5.65 or -8.60%) and Intellia Therapeutics (NTLA -$3.24 or -9.94%).

 

MY working trend (5 largest) lines:

… The greatest volume to the downside:  CRSP, SGMO, BTX, EDIT and VSTM

… Upside volume was weighted to:  MDXG, IONS, VCEL and BCLI

… Biggest $ downside: BLUE (-$13.60), SAGE (-$7.42), CRSP (-$5.46), RGNX (-$4.25) and ALNY (-$3.05)

 … Best moves to the $ upside: IONS (+$0.76), VCEL (+0.30), BCLI (+$0.18) and MDXG (+$0.12)

… Flats:  OSIR

 

The weekly count - decliners versus gainers – looks at the view from different angles:

……. look at the differences in decliners:

  • Tuesday’s decliners ranged from -0.22% <KOOL -$0.009 > to -10.44% <FATE -$1.14 > in 40 equities;
  • Monday’s decliners ranged from -0.21% <SAGE -$0.36 > to -6.82% <SLDB -$2.94 > in xx equities;
  • Friday’s decliners ranged from -0.03% <NTLA (-$0.01 > to -6.97% < MDXG -$0.28> in 24 equities;
  • Thursday’s decliners ranged from -0.24% < CRSP -$0.14> to -3.83% <ONCE -$3.27 > in 14 equities;
  • Wednesday’s decliners ranged from -0.13% <RGNX -$0.10 > to -8.59% <VYGR -$1.71 > in 30 equities;
  • Last Tuesday’s decliners ranged from -11% < KOOL -$0.0529> to -0.36% <IONS -$0.16 > in 13 equities;

Versus

… Look at the percentage’s (%) and spreads …

  • Tuesday’s gainers ranged from +1.71% <IONS +$0.76 > to +4.40% < BCLI +$0.18> in 4 equities;
  • Monday’s gainers ranged from +0.46% <FATE +$0.05 > to +18.8% <CUR +$0.22> in 18 equities;
  • Friday’s gainers ranged from +0.10% <OSIR +$0.01 > to +4.12% <BLFS +$0.87 > in 15 equities;
  • Thursday’s gainers ranged from +0.18% <BMRN +$0.18 > to +21.68% <BSTG +$0.70 > in 30 equities;
  • Wednesday’s gainers ranged from +0.14% <KOOL+$0.0006> to +4.13% <BTX +$0.095 > in 13 equities;
  • Last Tuesday’s gainers ranged from +0.36% < SAGE +$0.61> to +12.69% < MESO +$0.76> in 29 equities;

 

Daily analytics and metrics:

  • The Dow rose 197.65 points to 25,241.94.
  • The S&P 500 added 0.5% to 2,820.40.
  • The NASDAQ closed down -0.01% or -1.11 points at 7,840.77.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market:

  • Tuesday traded at 12.41, down -1.66%
  • Monday traded at 12.62, down -1.87%
  • Friday traded at 12.83, down -0.31%
  • Thursday traded at 12.87, up +6.36%
  • Wednesday traded at 11.94, down -1%
  • Last Tuesday traded at 12.66, down -6%

 

The iShares Russell 2000 (IWM) closed:

  • Tuesday was down -1.06%;
  • Monday was up +0.12%;
  • Friday was down -0.42%;
  • Thursday was up +0.68%;
  • Wednesday was up +0.28%;
  • Last Tuesday was up +0.43%;

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Tuesday was down -0.14%
  • Monday was down -0.06 %
  • Friday was down -0.08%
  • Thursday was up +0.10%
  • Wednesday was down -0.09%
  • Last Tuesday was up +0.75%

 

JULY sessions:

Tuesday closed NEGATIVE with 40 decliners, 4 advancers and 1 flat;

Monday (7/23) closed NEGATIVE with 25 decliners, 18 advancers and 2 flats;

Friday closed NEGATIVE with 24 decliners, 15 advancers and 5 flats;

Thursday closed POSITIVE with 14 decliners, 28 advancers and 2 flats;

Wednesday closed NEGATIVE with 30 decliners, 13 advancers and 2 flat;

Tuesday closed POSITIVE with 13 decliners, 29 advancers and 3 flat;

Monday (7/16) closed NEGATIVE with 32 decliners, 10 advancers and 3 flat;

Friday closed POSITIVE with 17 decliners, 25 advancers and 3 flat;

Thursday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Wednesday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Tuesday closed NEGATIVE with 29 decliners, 15 advancers and 1 flat;

Monday (7/9) closed POSITIVE with 18 decliners, 22 advancers and 5 flat;

Friday closed POSITIVE with 8 decliners, 35 advancers and 2 flat;

Thursday closed POSITIVE with 18 decliners, 23 advancers and 4 flat;

Wednesday (7/4) was a holiday;

Tuesday closed POSITIVE with 9 decliners, 33 advancers and 3 flat;

Monday (7/2) closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.